Bruce Liu is a partner at Simon-Kucher & Partners, leading its life sciences division in greater China.
Fresh Formulas for Growth: Assessing Asia in the New Year
The three key themes likely to shape pharma fortunes in 2024.
The Rising Importance of Patient Advocacy Innovations in Asia
Effective engagement—from research to reimbursement—is key.
Tapping New and Improved Drug Innovations in Asia
Attempts to capitalize on the region’s vibrant R&D scene are heating up.
Seizing On Asia’s Opportune Market for Novel Vaccines
The time is ripe to double down on local “market-fit” capabilities.
China’s 2022 NRDL Readout
Despite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.
Innovating the Go-to-Market Model in Asia
An ecosystem perspective is the first step.
Cracking the Code to Commercial Promise in Asia
Global go-to-market strategies in region require a revamped gameplan.
China’s 2022 NRDL Outlook
The 2022 National Reimbursement Drug List will see more pressures for new inclusions on the one hand, and more certainties for renewals on the other. At the same time, the process is becoming more interactive and transparent.
3 Steps to Navigate Rare Disease Market in China
The rare disease market in China can be summed up in three words: Exciting, challenging, and fast evolving. As such it’s quite a complicated space that requires a careful and strategic approach. In this article experts from Simon-Kucher discuss how best to navigate this landscape to reap the many opportunities available.
Asia’s Rise in The Global Pharma Industry
Continent has shed its ‘emerging’ status on world biopharma stage.
Real-World Evidence Is Becoming a Pivotal Component in Chinese Healthcare
Its use enables key processes such as early access, regulatory approval, and reimbursement listing.
One to Watch: China’s Cell and Gene Therapies Industry
Exploring the market’s emergence on the global stage.
China 2021: The NRDL Readout
China‘s 2021 National Reimbursement Drug List (NRDL) results are finally out, and this year features another major expansion of the NRDL formulary, with ongoing emphasis on innovations and some much anticipated breakthroughs in rare disease drug inclusions.
Maximizing China Access for Innovative Therapies
To maximize the potential of innovative therapies in the Chinese market, it’s important to have a holistic view of the full range of options and levers, prioritize and sequence the ones with the highest impacts, and develop an integrated strategy tailored to address the country’s unmet needs.
2 Commerce Drive Cranbury, NJ 08512